Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma by LaurenEBS | Sep 13, 2025
Isatuximab Cyclophosphamide Bortezomib and Dexamethasone Induction and Autologous Stem Cell Transplant in Newly Diagnosed Myeloma: Report of the Prospective Canadian Myeloma Research Group 008 Trial by LaurenEBS | Jun 13, 2024
Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial by LaurenEBS | Dec 13, 2023
A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma by LaurenEBS | Dec 13, 2021
Extended Follow-Up Safety and Efficacy Results of Belantamab Mafodotin (Belamaf) 1.92 Mg/Kg Or 2.5 Mg/Kg Combined with Pom and Dex for the Treatment of Relapsed/Refractory Multiple Myeloma by LaurenEBS | Sep 13, 2021
